Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Crossject S.A. is a pharmaceutical company specializing in the development of needle-free, pre-filled delivery systems known as Zeneo injectors. Its primary function is to provide a pain-free, user-friendly alternative to traditional hypodermic injection methods, aiming to enhance patient compliance and accessibility. The company's technology serves vital sectors in healthcare, impacting areas such as emergency medicine, chronic disease management, and biodefense. By eliminating the need for needles, Crossject's products address concerns related to needle-phobia, safety, and disposal challenges. With its pioneering delivery innovation, Crossject S.A. holds a significant role in the pharmaceutical market by potentially revolutionizing the administration of life-saving medications, enhancing care outcomes, and expanding access to treatments in various settings.
Negative free cash flow of -€11M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
€0.00
Net Income (TTM)
-€10M
▲ +10.4% YoY
Op. Margin
—
ROIC
-39.05%
▲ +8.3pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€11M
▲ +5.5% YoY
Op. Cash Flow (TTM)
-€10M
▼ -28.4% YoY
Net Debt
€17M
Cash & Equiv.
€5M
Continue Research